Table 1_The association between dietary fat quality and quantity and hospitalization duration in COVID-19 in Iranian patients: a cross-sectional study.docx by Farideh Shiraseb (11458982)

“…Linear and binary logistic regressions were employed for statistical analysis.…”

Data_Sheet_1_Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study.docx by Panagiotis Drakopoulos (5444162)

“…</p><p>Results: Under GnRH agonist treatment, serum AMH was significantly decreased vs. baseline on day 7 (mean change from baseline: −0.265 ng/mL; 95% confidence interval [CI], −0.395 to −0.135 ng/mL; p < 0.001). …”

Differences in FA between the OO group and the NW group using both TBSS analysis (Figure 3a) and VBA method (Figure 3b). by Baohui Lou (639539)

“…<p>(<b>3a</b>) Green represents mean FA skeleton of all participants, while red represents regions with significantly decreased FA in the OO group (<i>P</i><0.05, corrected for multiple comparisons). …”

DataSheet1_Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Study.DOCX by Si-Chun Gu (12135735)

“…</p><p>Results: Generalized estimating equation analyses revealed that the PCG group had significantly better improvement in UPDRS-III score at T1, T2, and T3 [time-by-group interaction, T1: β, −0.92 (95% CI, −1.59–−0.25; p = 0.01); T2: β, −2.08 (95% CI, −2.90–−1.27; p < 0.001); T3: β, −4.54 (95% CI, −5.37–−3.71; p < 0.001))]. The PCG group showed a greater decrease (rate of disease change) in the total UPDRS score between T0 and T2 [−2.23 (95% CI, −2.72–−1.73; p < 0.001) points per week vs. −0.21 (95% CI, −0.80–0.39; p = 0.50) points per week in the placebo group, p < 0.001]. …”

Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017 by Maria Gańczak (8519883)

“…DALYs due to non-communicable diseases (NCDs) decreased slightly (2.0%; 0.1–4.6). In 2017, Poland performed better than CE as a whole (ranked fourth for YLLs, sixth for YLDs, and fifth for DALYs) and achieved greater reductions in YLLs and DALYs than most CE countries. …”

Growth factors expression and ultrastructural morphology after application of low-level laser and natural latex protein on a sciatic nerve crush-type injury by Fernando José Dias (3174455)

“…Med:19.4%area). At week 8, a general reduction of VEGF expression was noted, remaining higher in F1 (Med:35.1; Q1.30.6; Q3.39.6%area) and LLLT&F1 (Med:18.5; Q1:16; Q3:25%area). …”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Data_Sheet_1_Body Weight Variability Increases Dementia Risk Among Older Adults: A Nationwide Population-Based Cohort Study.docx by Eun Roh (1526662)

“…</p><p>Methods: We performed a retrospective elderly cohort study from 19,987 participants with mean age 73 years old in the Korean National Health Insurance Service. …”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Image_1_Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.tif by Wen Wei (111015)

“…Compared with control group, estimated glomerular filtration rate (eGFR) level decreased less in SGLT-2i group (mean difference [MD] = −3.60, 95% CI, −5.90 to −1.30, p = 0.002; I² = 0%).…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_1_Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.docx by Wen Wei (111015)

“…Compared with control group, estimated glomerular filtration rate (eGFR) level decreased less in SGLT-2i group (mean difference [MD] = −3.60, 95% CI, −5.90 to −1.30, p = 0.002; I² = 0%).…”

3D tomographies of mid-diaphyseal cortical bone in the femur of a baseline control, age-matched control and unloaded C3H mouse. by Bing Li (43671)

“…Shown data present mean group values (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156222#pone.0156222.t001" target="_blank">Table 1</a> for units).…”

DataSheet_1_Predicting pathological complete response after neoadjuvant chemotherapy: A nomogram combining clinical features and ultrasound semantics in patients with invasive brea... by Ke-Nie Wang (13790545)

“…The decrease rate of the largest diameter was calculated by ultrasound after NAC and their cut-off points were determined among subtypes. …”

Free iCherry is released through a pore in the viral membrane, while the saponin-resistant content marker is retained under conditions expected to destabilize the capsid. by Sergi Padilla-Parra (166100)

“…A slow decrease of the EcpH-ICAM-1 signal over time in panels B and C is likely related to disruption of the viral membrane upon prolonged exposure to saponin.…”

DataSheet_1_Dynamics of O2 and pCO2 in a Southeast Asia seagrass meadow: Metabolic rates and carbon sink capacity.pdf by Wen-Chen Chou (9033482)

“…These results demonstrate that the metabolism and the relationship between NCP and pCO₂ in the seagrass meadows of Dongsha Island may deviate greatly from the global mean condition. To obtain a better assessment of the global potential of seagrass meadows as a nature-based solution for carbon sequestration, more regional-specific studies are still needed in the key regions, such as Indonesia and the Pacific archipelagos, that support extensive seagrass meadows but have not been charted.…”

A Personalized short-time Immunotherapy with Subcutaneous very low-dose Il-2 plus the Pineal Hormone Melatonin in advanced cancer patients with Persistent Lymphocytopenia by Paolo Lissoni (10019792)

“…Finally, it is known that lymphocytopenia may predict a negative prognosis in the advanced neoplasms, and a more negative significance is played by the occurrence of abnormally low values of lymphocyte-to-monocyte ratio (LMR), whose decline could depend on both lymphocyte decrease and monocyte increase. …”

The Bullfrog user interface showing the default filter criteria applied to two pairwise comparison files by Matthew A Zapala (55075)

“…., licensee BioMed Central Ltd</p> The default filter criteria include the following: a difference call of Increase (I), Marginal Increase (MI), Decrease (D) or Marginal Decrease (MD), a fold change (ratio) of greater than 1.8, an average difference change (Avg. …”

Additional file 5 of Organization of self-advantageous niche by neural stem/progenitor cells during development via autocrine VEGF-A under hypoxia by Taichi Kashiwagi (2430256)